06/29
Headlines

Biotech New Lows: Akebia Therapeutics (NASDAQ:AKBA), Galmed Pharmaceuticals (NASDAQ:GLMD), Tetralogic Pharmaceuticals (NASDAQ:TLOG), Dipexium Pharmaceuticals (NASDAQ:DPRX)

Kevin Long02 mins

Akebia Therapeutics Inc. (NASDAQ:AKBA) offered 5.9 million shares in its Thursday IPO at $17 a share, the high end of the stock’s expected price range. Among other therapeutics, the biopharma company is developing a once-daily oral therapy for patients with kidney disease. Akebia Therapeutics, Inc. (NASDAQ:AKBA) stock performance was -0.99% in last session and finished…

Read More

Best Stocks : Computer Task Group (NASDAQ:CTG), Xerox (NYSE:XRX), MGC Diagnostics (NASDAQ:MGCD), CECO Environmental Corp. (NASDAQ:CECE), Birks (NYSEMKT:BGI)

John Meady02 mins

Computer Task Group (NYSE:CTG) was downgraded by Zacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Wednesday. Computer Task Group Inc. (NASDAQ:CTG) belongs to Technology sector. Its net profit margin is 3.50% and weekly performance is -2.84%. On last trading day company shares ended up $14.01. Computer…

Read More

Stocks in Focus: Proteon Therapeutics, Inc. (NASDAQ:PRTO), Pandora Media Inc (NYSE:P), KCAP Financial, Inc. (NASDAQ:KCAP), Tarena International, Inc. (NASDAQ:TEDU), EMCORE Corporation (NASDAQ:EMKR)

John Meady02 mins

Proteon Therapeutics (NASDAQ:PRTO) Insider James E. Flynn bought 691,713 shares of the company’s stock in a transaction dated Monday, October 27th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $6,917,130.00. Proteon Therapeutics, Inc. (NASDAQ:PRTO) belongs to Healthcare sector. Its weekly performance is 2.30%. On last trading…

Read More

Healthcare Active Stocks: Arena Pharmaceuticals (NASDAQ:ARNA), Bristol-Myers Squibb (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), TherapeuticsMD (NYSEMKT:TXMD), Boston Scientific (NYSE:BSX)

Kevin Long03 mins

Arena Pharmaceuticals, Inc.’s (NASDAQ:ARNA ) shares dropped 9.4% following news that its CEO Jack Lief, has sold around 40% of his stake in the company. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was -5.29% in last session and finished the day at $5.01. Traded volume was 7.44million shares in the last session and the average volume…

Read More

Tech News

Tech Analysis & Market News

Skip to content ↓